annovis bio, inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. its lead compound is anvs401, which is in phase 2a clinical trials for the treatment of alzheimer's disease (ad), parkinson's disease, alzheimer's disease in down syndrome, and other chronic neurodegenerative disorders. the company is also developing anvs405 for protecting the brain after traumatic brain injury and/or stroke; and anvs301, which is in phase i clinical trials to increase cognitive capability in later stages of ad and dementia. annovis bio, inc. was founded in 2008 and is based in berwyn, pennsylvania.
Company profile
Ticker
ANVS
Exchange
Website
CEO
Maria Maccecchini
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
QR Pharma, Inc.
SEC CIK
Corporate docs
IRS number
262540421
ANVS stock data
Latest filings (excl ownership)
8-K
Annovis Announces Unblinding of the Buntanetap Phase Iii Data In Parkinson’s Disease
9 May 24
DEFA14A
Additional proxy soliciting materials
6 May 24
8-K
Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
6 May 24
8-K
Other Events
2 May 24
8-K
Departure of Directors or Certain Officers
1 May 24
424B5
Prospectus supplement for primary offering
1 May 24
ARS
2023 FY
Annual report to shareholders
29 Apr 24
DEFA14A
Additional proxy soliciting materials
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
8-K
Entry into a Material Definitive Agreement
26 Apr 24
Latest ownership filings
SC 13G/A
HIRSCHMAN ORIN
28 Nov 23
4/A
Mark K. White
22 Nov 23
4/A
Reid McCarthy
22 Nov 23
4/A
Michael B Hoffman
22 Nov 23
4/A
Maria-Luisa Maccecchini
22 Nov 23
4/A
Henry Hagopian III
22 Nov 23
4/A
Claudine Bruck
22 Nov 23
4
Reid McCarthy
21 Nov 23
4
Michael B Hoffman
21 Nov 23
4
Mark K. White
21 Nov 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 6.35 mm | 6.35 mm | 6.35 mm | 6.35 mm | 6.35 mm | 6.35 mm |
Cash burn (monthly) | 3.12 mm | 2.14 mm | 4.95 mm | 3.53 mm | 3.12 mm | 2.85 mm |
Cash used (since last report) | 22.96 mm | 15.70 mm | 36.42 mm | 25.97 mm | 22.96 mm | 20.96 mm |
Cash remaining | -16.61 mm | -9.35 mm | -30.07 mm | -19.62 mm | -16.61 mm | -14.60 mm |
Runway (months of cash) | -5.3 | -4.4 | -6.1 | -5.6 | -5.3 | -5.1 |
Institutional ownership, Q3 2023
12.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 30 |
Opened positions | 3 |
Closed positions | 1 |
Increased positions | 6 |
Reduced positions | 9 |
13F shares | Current |
---|---|
Total value | 10.54 bn |
Total shares | 1.41 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Adage Capital Partners GP, L.L.C. | 300.00 k | $2.85 bn |
Hirschman Orin | 293.36 k | $2.98 mm |
Vanguard | 258.53 k | $2.45 bn |
BLK Blackrock | 96.28 k | $913.71 mm |
Geode Capital Management | 56.04 k | $531.98 mm |
AIGH Capital Management | 48.94 k | $464.45 mm |
Wescott Financial Advisory | 41.61 k | $394.85 mm |
Merit Financial | 41.20 k | $390.99 mm |
Sterling Investment Advisors | 34.37 k | $326.21 mm |
Redmond Asset Management | 34.08 k | $323.42 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
20 Nov 23 | Henry Hagopian III | Common Stock | Grant | Acquire A | No | No | 6.1 | 820 | 5.00 k | 1,820 |
20 Nov 23 | Bruck Claudine | Common Stock | Other | Acquire J | No | No | 0 | 0 | 0.00 | 6,567 |
20 Nov 23 | Hoffman Michael B | Common Stock | Grant | Acquire A | Yes | No | 6.1 | 163,880 | 999.67 k | 223,357 |
20 Nov 23 | Reid McCarthy | Common Stock | Other | Acquire J | No | No | 0 | 0 | 0.00 | 7,305 |
20 Nov 23 | Maccecchini Maria-Luisa | Common Stock | Grant | Acquire A | No | No | 6.1 | 40,970 | 249.92 k | 1,098,459 |
News
Annovis Bio CEO Outlines Next Steps in Alzheimer's Research After Mixed Phase II/III Trial Results
6 May 24
12 Health Care Stocks Moving In Tuesday's Intraday Session
30 Apr 24
HC Wainwright & Co. Reiterates Buy on Annovis Bio, Maintains $30 Price Target
30 Apr 24
S&P 500 Edges Higher; ON Semiconductor Earnings Top Views
29 Apr 24
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
29 Apr 24
Press releases
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson's Disease
9 May 24
Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
6 May 24
Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
2 Apr 24
Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer's Disease
20 Mar 24
Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer's Disease
14 Feb 24